What's Happening?
Circio and Tcelltech are collaborating to develop next-generation in vivo CAR-T and TCR-T cell therapies using their respective technologies. The partnership combines Circio's circVec circular RNA expression technology with Tcelltech's non-viral, high-cargo
capacity nanoSMAR vector platform. This collaboration aims to enhance and sustain CAR/TCR expression in engineered T-cells without relying on viral vectors, which have safety concerns. The initial phase will focus on proof-of-concept studies to evaluate gene expression in primary human T cells, followed by functional testing of CD19-directed CAR T cells for tumor cell killing efficacy.
Why It's Important?
This collaboration represents a significant advancement in the field of engineered T-cell therapies, which have revolutionized cancer treatment. By moving towards non-viral, in vivo approaches, the partnership addresses the complexities and safety issues associated with traditional ex vivo manufacturing. The development of scalable and accessible T-cell therapies could transform cancer treatment, making it more widely available and cost-effective. This innovation could also pave the way for new therapeutic avenues in other diseases, enhancing the overall impact of gene therapy technologies.
What's Next?
The collaboration will proceed with a staged research program to validate the effectiveness of the combined technologies. Successful outcomes could lead to further development and commercialization of these therapies, potentially expanding their application beyond cancer to other diseases. The partnership aligns with Circio's strategy to explore multiple modalities and delivery systems, which could result in identifying optimal technology combinations for various therapeutic applications.
